TILS.L Regulatory News (TILS)

31 Mar 2008 08:00

ReGen Therapeutics PLC31 March 2008 31 March 2008 embargoed for 9am Research Update In-vivo study shows ReGen's ColostrininTM to be non-allergenic and able toprevent allergic inflammation ReGen Therapeutics Plc ('ReGen') is pleased to announce a report of a studyconducted by Dr Istvan Boldogh* of the University of Texas Medical Branch waspublished on the 27 March on line in the International Archives of Allergy andImmunology. This study shows that ColostrininTM , ReGen's nutraceutical product,being marketed by Metagenics Inc., California for the 'support of healthy brainageing and cognition', is not only non-allergenic, but prevents allergicinflammation due to common indoor and outdoor allergens. Currently Metagenics and or its subsidiaries are selling ColostrininTM inAustralasia since July 2007 and North America since October 2007. Headquarteredin San Clemente, California, Metagenics is a leading developer, manufacturer andmarketer of nutraceuticals, dedicated to researching and evaluating the effectsof natural ingredients on genetic expression and protein activity. Additionally,on 25 March 2008 ReGen announced its first approval to launch in the EuropeanUnion in Cyprus through Golgi Pharmaceuticals Ltd its distributor for thatmarket. Highlights of the study are as follows: • The objective of the study was to investigate potential allergic responses to ColostrininTM and its impact on allergic sensitisation and inflammation caused by common allergens to underpin its safe use as a human nutraceutical . A spray-dried whole Colostrum product which is commercially available as a nutraceutical was used as a control • The study used a well characterised mouse model of allergic airway inflammation • ColostrininTM (given orally, intranasally or intraperitoneally) significantly decreased IgE/IgG1 production, airway eosinophilia, mucin production and hypersensitivity induced by allergenic extracts from ragweed pollen and house dust mites • In contrast, Colostrum, from which ColostrininTM is derived, induced positive inflammatory responses Commenting on these findings Dr. Marian Kruzel (a co-author of the publicationand a scientific advisor to ReGen) said: ' These findings are entirelyconsistent with Colostrinin'sTM safety profile and use to support healthycognition through significant reduction of reactive oxygen species (ROS) buildup.' Percy Lomax, Chairman and Chief Executive Officer added: 'The data shows thatColostrininTM may be used in humans without concern about experiencing anallergic reaction. This is in contrast to other less refined dairy-derivedproducts, in particular whole colostrum, which is a significant US dietaryproduct. We believe these findings will give impetus to the marketing ofColostrininTM. Notes: \* To read the full report please go to http://www.karger.com and search for theInternational Archives of Allergy and Immunology 2008;146:298-306. This studywas conducted by Dr Istvan Boldogh at the University of Texas Medical Branch,Galveston, Texas, USA. ReGen has a sponsored research agreement with theUniversity of Texas Medical Branch, Galveston, Texas, USA. A complete copy of the paper will be added to the ReGen website(www.regentherapeutics.com) soon. For further information, please contact: Percy LomaxReGen Therapeutics PlcTel: 020 7153 4920 Roland Cornish/Felicity GeidtBeaumont Cornish LimitedTel: 020 7628 3396 This information is provided by RNS The company news service from the London Stock Exchange